Fourteen studies comprising 2883 patients reported the POAF prevalence
in patients pretreated with a statin or placebo25-38 . Statin was correlated to a reduced
prevalence of POAF (312/1456 [21.4%] versus 393/1427 [27.5%]).
We encountered a statistically significant difference between the two
considered groups (OR 0.71; 95% CI: 0.60 to 0.85, p-value = 0.0001).
There was severe heterogeneity observed between the 14 studies
(I2= 69%) (Figure 4 ). However, If we
only consider studies with ≥ 199 patients, the results are divergent (OR
0.89; 95% CI: 0.74 to 1.09, p-value = 0.26 ; I2=
74%)
(Figure
5 ).